The Expanding Role of Somatostatin Analogs in the Management of Neuroendocrine Tumors

por Wolin, Edward M.
Publicado 2012

Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations

por Wolin, Edward M.
Publicado en Oncologist (2015)

Single Subcutaneous Nodule as Initial Presentation of Atypical Lung Carcinoid

por Yu, Run, Wolin, Edward, Fan, Xuemo
Publicado en World J Oncol (2010)

Primary hepatocellular carcinoma (“hepatoid” carcinoma) of the pancreas: a case report and review of the literature

por Steen, Shawn, Wolin, Edward, Geller, Stephen A, Colquhoun, Steven
Publicado 2013

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocri...

por Wolin, Edward M., Hu, Ke, Hughes, Gareth, Bouillaud, Emmanuel, Giannone, Vanessa, Resendiz, Karina Hermosillo
Publicado 2013

Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors

por Wolin, Edward M., Manon, Amandine, Chassaing, Christophe, Lewis, Andy, Bertocchi, Laurent, Richard, Joel, Phan, Alexandria T.
Publicado en J Gastrointest Cancer (2016)

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States

por Wolin, Edward M., Leyden, John, Goldstein, Grace, Kolarova, Teodora, Hollander, Ron, Warner, Richard R.P.
Publicado en Pancreas (2017)

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

por Singh, Simron, Granberg, Dan, Wolin, Edward, Warner, Richard, Sissons, Maia, Kolarova, Teodora, Goldstein, Grace, Pavel, Marianne, Öberg, Kjell, Leyden, John
Publicado en J Glob Oncol (2016)

Patient‐Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo‐Controlle...

por Fisher, George A., Wolin, Edward M., Liyanage, Nilani, Pitman Lowenthal, Susan, Mirakhur, Beloo, Pommier, Rodney F., Shaheen, Montaser, Vinik, Aaron
Publicado en Oncologist (2017)

Peptide Receptor Radionuclide Therapy with Lu-177 Octreotate in patients with Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years Assessment

por Delpassand, Ebrahim S., Hamiditabar, Mohammadali, Ali, Muzammil, Roys, Joseph, Wolin, Edward M., O’Dorisio, Thomas M., Ranganathan, David, Strosberg, Jonathan R.
Publicado en Clin Nucl Med (2017)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis

por Rustgi, Sheila D., Oh, Aaron, Yang, Jeong Yun, Kang, Dasol, Wolin, Edward, Kong, Chung Y., Hur, Chin, Kim, Michelle K.
Publicado en BMC Cancer (2021)

Pharmacokinetic study of aldoxorubicin in patients with solid tumors

por Mita, Monica M., Natale, Ronald B., Wolin, Edward M., Laabs, Brenda, Dinh, Hillary, Wieland, Scott, Levitt, Daniel J., Mita, Alain C.
Publicado en Invest New Drugs (2014)

Effect of Lanreotide Depot/Autogel on Urinary 5‐Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors

por Pavel, Marianne E., Phan, Alexandria T., Wolin, Edward M., Mirakhur, Beloo, Liyanage, Nilani, Pitman Lowenthal, Susan, Fisher, George A., Vinik, Aaron I.
Publicado en Oncologist (2018)

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

por Caplin, Martyn E., Pavel, Marianne, Phan, Alexandria T., Ćwikła, Jarosław B., Sedláčková, Eva, Thanh, Xuan-Mai Truong, Wolin, Edward M., Ruszniewski, Philippe
Publicado en Endocrine (2020)

Small bowel carcinoid: Location isn’t everything!

por Hari, Danielle M, Goff, Stephanie L, Reich, Heidi J, Leung, Anna M, Sim, Myung-Shin, Lee, Ji Hey, Wolin, Edward, Amersi, Farin
Publicado 2013

Impact of (68)Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician’s Perspective

por Herrmann, Ken, Czernin, Johannes, Wolin, Edward M., Gupta, Pawan, Barrio, Martin, Gutierrez, Antonio, Schiepers, Christiaan, Mosessian, Sherly, Phelps, Michael E., Allen-Auerbach, Martin S.
Publicado en J Nucl Med (2014)

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial

por Lombard-Bohas, Catherine, Yao, James C., Hobday, Timothy, Van Cutsem, Eric, Wolin, Edward M., Panneerselvam, Ashok, Stergiopoulos, Sotirios, Shah, Manisha H., Capdevila, Jaume, Pommier, Rodney
Publicado en Pancreas (2015)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

por Yao, James C, Chan, Jennifer A, Mita, Alain C, Kundu, Madan G, Hermosillo Reséndiz, Karina, Hu, Ke, Ravichandran, Shoba, Strosberg, Jonathan R, Wolin, Edward M
Publicado en Onco Targets Ther (2017)

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

por Wolin, Edward, Mita, Alain, Mahipal, Amit, Meyer, Tim, Bendell, Johanna, Nemunaitis, John, Munster, Pam N., Paz-Ares, Luis, Filvaroff, Ellen H., Li, Shaoyi, Hege, Kristen, de Haan, Hans, Mita, Monica
Publicado en PLoS One (2019)

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

por Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
Publicado en Onco Targets Ther (2017)